PRODUCTS
APIs and intermediates
No data

No data

  • Gefitibib
  • Gefitibib
  • Gefitibib
  • Gefitibib
  • Gefitibib
Gefitibib
Gefitibib
Gefitibib
Gefitibib
Gefitibib
+

Share

Gefitibib



Summary:

Gefitinib is a highly specific anti-tumor targeted therapeutic drug developed by AstraZeneca in the UK.

CAS:

184475-35-2

Standard:

USP/BP

Purity:


Keywords:

API and Intermediates

  • Product description
  • Product Intro

    Gefitinib is a highly specific anti-tumor targeted therapeutic drug developed by AstraZeneca in the UK. It is the first molecular targeted drug for the treatment of non-small cell lung cancer. It plays a role by selectively inhibiting the signal transduction pathway of epidermal growth factor receptor tyrosine kinase (EGFR-TK).
    Function

    Gefitinib blocks EGFR signal transduction pathway on cell surface, hinders tumor growth, metastasis and angiogenesis, and can induce tumor cell apoptosis.
    Application

    1. Gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor,.

    2. An inhibitor of epidermal growth factor receptor lysine kinase (EGFR TK). For the treatment of non stem cell lung cancer. But the side effects are great.

Messages

Note: Please provide accurate and detailed information, and our professional staff will contact you as soon as possible!

Recommended products